SCHEMBL2080587

SCHEMBL2080587

NC(=O)C(Br)CCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17545277 0.85 ALDH1A1 (0.36)
SCHEMBL28465687 0.80 LCK (0.44)
SCHEMBL29633207 0.79 ALDH1A1 (0.35)
SCHEMBL7519796 0.77
SCHEMBL55902 0.77
SCHEMBL7519715 0.77
SCHEMBL971093 0.76
SCHEMBL27729662 0.76
SCHEMBL2082092 0.74
SCHEMBL7068407 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101307143-A Organic-inorganic composite lamellar compound with regular arrangement bromium and method for preparing same UNIV SHANGHAI (CN) 2008-11-19 CN claimed
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2024-04-11 US disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 EP disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
EP-3585775-B1 AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI SA (FR) 2022-04-06 EP disclosed
US-10392366-B2 Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2019-08-27 US disclosed
EP-3126336-B1 SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI SA (FR) 2018-12-05 EP disclosed
WO-2018153849-A1 AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI (FR) 2018-08-30 WO disclosed
US-20180237419-A1 AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI (FR) 2018-08-23 US disclosed
CN-1821226-A Antipicornaviral compounds, their preparation and use AGOURON PHARMA (US) 2006-08-23 CN disclosed
WO-2006068276-A1 HAIR PROCESSING AGENT AND METHOD FOR PERMANENT WAVING HAIR SHOWA DENKO K.K. (JP) 2006-06-29 WO disclosed
CN-1198838-C Anti-small RNA virus compound and preparation method and application thereof AGOURON PHARMA (US) 2005-04-27 CN disclosed
CN-1311793-A Anti-small RNA virus compound and preparation method and application thereof AGOURON PHARMA (US) 2001-09-05 CN disclosed
US-5112980-A Intermediates for herbicides MONSANTO COMPANY (US) 1992-05-12 US disclosed
EP-0435844-A1 Substituted pyridine compounds MONSANTO COMPANY (US) 1991-07-03 EP disclosed
US-4196124-A ANTIOBESITY AGENTS SCHERING CORPORATION (US) 1980-04-01 US disclosed
US-4173566-A CHEMICAL INTERMEDIATE FOR AN ANTIOBESITY AGENT SCHERING CORPORATION (US) 1979-11-06 US disclosed
US-4140780-A ANTIOBESITY AGENTS SCHERING CORPORATION (US) 1979-02-20 US disclosed
US-4052383-A ANTIOBESITY SCHERING CORPORATION (US) 1977-10-04 US disclosed